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Abstract
Hydroxymethylcytosine (5hmC) methylation is well-known epigenetic mark impact-
ing genome stability. In this paper, we address the existing 5hmC measure ∆β and
discuss its properties both analytically and empirically on real data. Then we intro-
duce several alternative hydroxymethylation measures and compare their properties
with those of ∆β. All results are illustrated by means of real data analyses.
1 Introduction
DNA methylation is known to play a crucial role in the development of such diseases as
diabetes, schizophrenia, and some forms of cancer; see [2] and references therein. In order
to address the possible impact of DNA methylation on the various biological functions and
processes, a whole string of extensive biological, bioinformatical, and statistical analyses
was developed in the past years [2]. A substantial part of the methods introduced in
those analyses aims at quantifying the actual level of DNA methylation, in particular on
a single nucleotide resolution in genomic DNA.
At some point, this research indicated that the obtained DNA methylation level1 can
be split into hydroxymethylcytosine (5hmC) and 5-methylcytosine (5mC) components,
with 5mC playing an important role in gene silencing and genome stability [1]. The
second component, 5hmC methylation, was first discovered in 2009 as an another form
of cytosine modification [6]. Since then, its function as an intermediate in active DNA
demethylation and an important epigenetic regulator of mammalian development, as well
as its role as a possible epigenetic mark impacting genome stability has come into the
spotlight [1, 5, 7, 13]. At that point, the question concerning reliable detection and
accurate quantification of 5hmC emerged.
Until now, two key techniques for the quantification of 5hmC levels, the TET-assisted
bisulfite sequencing (TAB-seq) technique and the oxidative bisulfite sequencing (oxBS-seq)
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1e.g., [6] refers to it as ”total DNA methylation”
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technique23, were established. When applied for the quantification of 5hmC methylation,
the TAB-seq technique uses the fact that 5mC can be converted to 5hmC in mammalian
DNA by TET emzymes [6, 7]. In the context of this technique, 5hmC sites are blocked by
means of β-glucosyltransferase (βGT) in the first step. Then a recombinant mouse TET1
enzyme is applied to convert 5mC to 5caC. Finally, by means of bisulfite treatment, 5caC
is converted to uracil, leaving only glucosylated 5hmC to be read as a cytosine. Note that
the TAB-seq technique is known to be cost-intensive due to the use of TET1 protein [1];
this may become an issue when applying this technique for 5hmC quantification.
In the context of the second technique, DNA methylation levels can be obtained from the
bisulfite sequencing (BS-seq) procedure [1]. However, this procedure can only differentiate
between methylated and unmethylatedd cytosine bases, and cannot discriminate between
5mC and 5hmC. To determine the level of 5hmC at a considered nucleotide position, the
oxidative bisulfite sequencing (oxBS-seq) approach can be applied. This approach yields
C’s only at 5mC sites while oxidating 5hmC to 5-formylcytosine (5fC) and later converting
them to uracil. As a result, an amount of 5hmC at each particular nucleotide position
can be determined as the difference between the oxBS-seq (which identifies 5mC) and the
BS-seq (which identifies 5mC+5hmC) readouts. Indeed, such substraction seems to make
sense biochemically, even if from a statistical point of view it may clearly increase the
noise level in the assay.
In order to quantify the level of 5hmC in the context of the oxBS-technique, the following
quantity is introduced in [3, 4]
∆βoxBS = βBS − βoxBS = MBS
MBS + UBS + 100
− MoxBS
MoxBS + UoxBS + 100
. (1)
Here M is the intensity of the methylated allele, U is the intensity of the unmethylated
allele, βBS is the methylation level obtained from the BS-seq method, and βoxBS is the
methylation level derived by means of the oxBS-seq method. As stated in [3, 4], the
quantity ∆βoxBS has to be computed for each single CpG and each single sample4 and
can be interpreted as a “measure of hydroxymethylation” and “a reflection of the 5hmC
level at each particular probe location” [3]. This measure can then be applied in the
screening step so as to exclude from further analysis those CpGs that do not appear to
contain hydroxymethylation.
Due to its definition, ∆βoxBS can take values between -1 and 1, where negative values of
2An alternative method that can also be applied for the simultaneous quantification of 5mC and
5hmC, the so-called liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, is presented
in [5, 13]. In particular, [13] shows that 5hmC is an oxidation product of 5-methylcytosine which arises
slowly within the first 30 hours after DNA synthesis and remains (almost) constant during the cell cycle.
3Our research results are based on the real data derived by means of the oxBS-technique.
4Symmetrically, in cases where hydroxymethylation is to be quantified in the context of the TAB-seq
- method, the quantity
∆βTAB = βBS − β5hmC = MBS
MBS + UBS + 100
− M5hmC
M5hmC + U5hmC + 100
, (2)
with βBS as above and β5hmC derived by means of the TAB-seq method, can be computed for each single
probe and each single CpG; for more details see [7].
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∆βoxBS “represent false differences in methylation score between paired BS-only and oxBS
data sets” and may be interpreted as a “background noise” [3]. This interpretation has
meanwhile been questioned in [11], where the authors discuss the “naive” estimation of the
5hmC level via the difference of two β values as proposed in [3, 4, 7] and introduce a model
for describing and estimating the proportions of 5mC and 5hmC via beta distributed
random variables. The aim of such modeling was to disallow negative proportions; the
corresponding model is implemented in the the R-package OxyBS.
While using ∆βoxBS for the identification of significantly hydroxymethylated cytosines, the
issue of an appropriate ∆βoxBS threshold arises. In [4], the authors introduced ∆βoxBS > 0
as an indicator for a given CpG to be hydroxymethylated; for all CpGs with low or negligible
levels of 5hmC, ∆βoxBS “may be negative as a consequence of inevitable random noise.”
In [3], the threshold for ∆βoxBS has been set to 0.3 or 30%. However, it is not evident,
whether the thresholds for ∆βoxBS proposed in [3, 4] can be applied for any given data
set or whether such threshold should be derived for each data set separately.
In the present paper we will first address the applicability of the ∆βoxBS measure (in
the following notation just ∆β) for quantification of 5hmC levels and indicate limitations
of this measure. Therefore we will discuss properties of ∆β, both analytically and on
data. Then we will introduce a number of alternative hydroxymethylation measures and
compare their properties and similarity with those of ∆β. All results will be illustrated
by means of real data analyses.
Data analyses presented here were performed on two real data sets derived from brain and
whole blood tissues. This fact makes these analyses particularly interesting, since global
5hmC levels are known to differ substantially between different tissue types [3] and, in
particular, human brain is known to have the highest global levels of both 5hmC and
5mC, with more than 1000 times greater than the levels in blood [1, 8, 15]. Note that
also in [3] the ∆β measure is analyzed on brain and whole blood tissue.
2 On the applicability of ∆β as a measure for 5hmC
levels
Given the methylated and unmethylated intensities M and U, the methylation level of
the particular probe can be described by the methylation proportion
β =
M
M + U + 100
(3)
as introduced in [9]. Thus, the 5hmC measure ∆βoxBS in (1) is just the difference of two
methylation proportions as derived from BS-seq and oxBS-seq treatment, respectively.
However, this simple definition, while appearing to be plausible at first, leads to a number
of ambiguities. First, the outcomes of ∆β are usually interpreted as follows [3]: Positive
values of ∆β are taken as an indicator for substantial hydroxymethylation, whereas small
values of ∆β indicate no or only nonsubstantial hydroxymethylation. Negative values of
∆β are considered as resulting from background noise. In the sequel, we will analyze each
3
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Figure 1: On the applicability of ∆β as a 5hmC measure: the case with ∆β > 0. The
magenta bars correspond to the MBS intensities, the black bars describe the MoxBS in-
tensities, the blue bars correspond to the UBS intensities, and the green bars correspond
to the UoxBS intensities. It is clear from the left-hand panel that none of the data points
show any substantial 5hmC level, but due to ∆β > 0 they will nevertheless be selected
as hydroxymethylated probes.
of these cases individually and show the limitations of the above-mentioned interpreta-
tions. In addition, we will have a closer look at the correction term 100 appearing in the
denominators in (1) and address possible consequences of this particular choice.
The first ambiguity arising from (1) concerns the application of ∆β as a 5hmC measure
in general. Even if both components in the difference (1) do represent the respective
methylation proportions for BS and oxBS data, these proportions are calculated on two
different bases: the proportion βBS represents the methylation proportion based on the
global BS methylation intensity MBS +UBS, whereas the proportion βoxBS represents the
methylation proportion based on the global oxBS methylation intensity MoxBS + UoxBS.
Thus, a direct comparison of these two proportions is difficult to justify and, as a result,
the interpretation of ∆β as “a reflection of the 5hmC level at each particular probe”
suggested in [3] is not well founded. A graphical illustration of this issue is presented in
Figure 1. In particular, as that figure shows, all ten simulated data points satisfy both
MBS < MoxBS and UBS < UoxBS
simultaneously.
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Figure 2: On the applicability of ∆β as a 5hmC measure: the case with ∆β < 0. Notations
are the same as in Figure 1. Note that the left-hand panel suggests that all ten data points
do exhibit a substantial level of 5hmC, whereas the right-hand panel shows negative ∆β
values.
That is, for each of these ten points the BS intensities are lower than the oxBS intensities
which intuitively corresponds to the interpretation ”no positive 5hmC observed”. On the
other hand, the condition ∆β > 0 holds for each of ten considered data points.
Another ambiguity arising in using the measure ∆β is an adequate interpretation of its
negative outcomes. In [3], the authors state that only probes with ∆β > 0 “represent
potential sites of 5hmC” and that negative values of ∆β “...are likely to reflect background
noise generated by the method...”; this view was also shared in [4]. However, such an
interpretation does not seem to be plausible according to our discussion on ∆β as a
difference of two methylation proportions βBS and βoxBS. Figure 2 illustrates this issue
for ten simulated data points that satisfy both
MBS > MoxBS and UBS > UoxBS,
although the condition ∆β < 0 holds. Thus, these data points show a positive 5hmC level
due to their BS intensities exceeding their oxBS intensities, but they will not be detected
by the measure ∆β as being substantially hydroxymethylated.
One of the main advantages of the measure β, which has also contributed to its common
application as a methylation measure, is its intuitive interpretation as an approximation
of the percentage of methylation [10]; here β = 0 denotes unmethylated probes and β = 1
denotes fully methylated probes. Unfortunately, this interpretation does not carry over
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to the measure ∆β. Indeed, in (1) the condition ∆β = 0 solely implies
MBS
MoxBS
=
UBS + 100
UoxBS + 100
and it is unclear how this last equality should be interpreted in terms of the observed
5hmC level. Moreover, Figure 3 demonstrates that we can get ∆β = 0 in cases where
MBS < MoxBS and UBS < UoxBS
(i.e., ”no substantial 5hmC level observed”, see both upper panels in Figure 3) as well as
in cases where
MBS > MoxBS and UBS > UoxBS
(i.e., ”a substantial 5hmC level observed”, see both lower panels in Figure 3).
Altogether, our analyses of the three cases ∆β > 0, ∆β = 0, and ∆β < 0 has shown that
their usual respective interpretations as indicators of substantial hydroxymethylation, no
hydroxymethylation, and noise are problematic.
Next, when analyzing the 5hmC measure ∆β in (1), the question arises why one chooses
the number 100 in the denominators MBS + UBS + 100 and MoxBS + UoxBS + 100. This
choice seems to stem from the practical convention in the definition of β-values [10], and
thus was carried over to the definition of ∆β as well [3, 7]. As a matter of fact, there is no
strong reason why the correction term 100 in (3) should not be replaced with another value
α > 0. This leads to the following more general definition of the methylation proportion
β(α) =
M
M + U + α
, (4)
with α > 0.
While one can safely argue that the actual choice of the parameter α is not crucial for
the interpretation of the methylation proportion β(α) itself (see [10]), we will now argue
that the choice of α can become critical when using the sign of the quantity
∆β(α) = βBS − βoxBS = MBS
MBS + UBS + α
− MoxBS
MoxBS + UoxBS + α
, (5)
as an indicator for hydroxymethylation. To this end, we will show in Appendix 6.1.3
that, under certain conditions, the sign of ∆β(α) can change from positive to negative or
vice versa if α varies; for an illustration see Figure 4. We will also give a formula for the
corresponding point of sign change, which we henceforth denote by α∗.
In Table 1, we show that a notable percentage of CpGs in our data sets of blood and
brain tissue exhibits a sign change of ∆β(α). Of these, a substantial percentage has a
value of α∗ being less than or equal to 1000. From a practical point of view, these results
imply that stating whether or not a particular CpG exhibits a positive level of 5hmC can
depend strongly on the choice of the correction parameter α.
6
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Figure 3: On the applicability of ∆β as a 5hmC measure: the case with ∆β = 0.
Notations are the same as in Figure 1 above.
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Figure 4: Dependence of ∆β(α) on the choice of α: ∆β(α) changing its sign from posi-
tive to negative (left-hand panel) and from negative to positive (right-hand panel) as α
increases. Note that this result refers to a given CpG site and a given sample.
Table 1: This table demonstrates that for a substantial percentage of CpGs in our data
sample the measure ∆β(α) may change its sign for varying α. Since a noticeable part of
such CpGs change their sign in a given point α∗ left from 200, we can conclude that even
small deviations from the chosen value α = 100 may lead to considerable changes in the
set of CpGs that are flagged as exhibiting a positive value of 5hmC. In this sense, the
measure ∆β(α) is not robust with respect to the choice of the correction parameter α.
In the context of the dependence of ∆β(α) on the choice of α, a question concerning
the possible impact of this choice on the percentage of CpG sites satisfying the condition
∆β(α) > 0 arises, for each given sample. As Figure 5 suggests, this percentage converges
to a certain constant value as α increases. For more details on this topic see the discussion
below.
Finally, it follows from (5) that ∆β ranges between -1 and 1. Such a limited range of
8
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brain tissue blood tissue
Figure 5: Percentage of CpGs satisfying ∆β(α) > 0: a real data example for four given
samples and both given tissues. Here α = 10 (light blue bars for brain and grey bars for
blood tissue), α = 100 (blue bars for brain and red bars for blood tissue) and α = 1000
(dark blue bars for brain and dark red bars for blood tissue) were considered. Note that
the considered percentage increases with increasing values of α and that this effect is most
observable in case of blood tissue.
possible values can become an issue, for instance, if after the completion of the screening
step one is looking for appropriate statistical methods for the further analysis of the ∆β
values, such as linear regression.
To summarize, in the present section we stated a couple of limitations of the 5hmC
measure ∆β(α) which make its practical applicability for quantification of 5hmC levels
questionable. In the next section we will address these limitations and propose a number
of alternative 5hmC measures.
3 Alternative 5hmC measures
As discussed in the previous section, the 5hmC measure ∆β(α) demonstrates a number
of shortcomings such as a lack of interpretation or its dependence on the choice of the
correction term α. To overcome such shortcomings, alternative 5hmC measures may
become a solution.
Thus, in the present section we will first introduce a number of alternative measures which
can be applied for detection of CpGs with a positive level of 5hmC. Further, following the
analysis pattern proposed for the measure ∆β(α), we will discuss the basic properties of
these measures and compare them to ∆β(α).
The first 5hmC measure we propose is based on the so-called m-value [10] given by a
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transformation of β = β(α) as
m = log2
β
1− β . (6)
While the m-value does not have an immediate and straightforward interpretation such
as the measure β, it was shown that it can outperform β in quantifying the level of
methylation, at least at high and low methylation levels; see [10] for more discussion.
Moreover, due to an unbounded range of possible values, a wider spectrum of statistical
methods can be used for the analysis of such m-values as compared to the number of
methods applicable to β values.
By adopting the idea of ∆β defined as a difference of two respective β values, we now
consider the difference of two respective m-values and introduce the measure
∆m = mBS −moxBS = log2
βBS
1− βBS − log2
βoxBS
1− βoxBS (7)
as a possible alternative to the 5hmC measure ∆β. Note that, in contrast to (6), there
is no formal transformation between ∆m and ∆β that would render ∆m as a function of
∆β; see the Appendix 6.2.2 for more details.
As before, we now make the dependence of β and ∆β on the correction parameter α
explicit by writing β(α) and ∆β(α). This dependence then carries over to m and ∆m,
so that we will henceforth write m(α) and ∆m(α). This latter dependence can be made
explicit by using standard calculations to transform (7) into
∆m(α) = log2
MBS
MoxBS
+ log2
UoxBS + α
UBS + α
. (8)
This is the expression for ∆m(α) we will use in the further discussions.
Next, we recall that CpGs with positive ∆β(α) are typically considered as showing a
substantial level of 5hmC; see, e.g., [3]. In the Appendix 6.2.1 we will show that the
condition ∆m(α) > 0 holds in the same cases as the condition ∆β(α) > 0 is satisfied.
Thus we can state that
at the end of the screening step, the two criteria ∆m > 0 and ∆β > 0 will
flag the same CpG sites.
In this sense, both hydroxymethylation measures are comparable and can be used inter-
changeably in detecting CpGs with a positive level of 5hmC. On the other hand, given
that ∆m(α) can take values on the entire real line, a wider range of statistical methods
can be applied for the further analysis of this hydroxymethylation measure.
As a matter of fact, the two measures ∆β(α) and ∆m(α) will always have the same sign,
for any given sample and CpG. This result, while contributing to the comparability of
two 5hmC measures, will at the same time lead to similar limitations for the interpreta-
tion of the measure ∆m(α) as for ∆β(α). First, ∆m(α) will evidently exhibit the same
ambiguities in the interpretation of its values as ∆β(α) does; that is, it is not evident how
the conditions ∆m(α) > 0, ∆m(α) = 0 and ∆m(α) < 0 can be interpreted in terms of
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the 5hmC level observed for a given CpG and sample. Second, the value of ∆m(α) will
obviously depend on the choice of the correction term α, just as the measure ∆β(α) does.
In particular, ∆m(α) may change its sign from positive to negative and vice versa under
the same conditions the measure ∆β(α) does. This issue is discussed in the Appendix
6.2.3 and 6.2.4; for an illustration see Figure 6.
Figure 6: ∆m(α) changing its values from positive to negative (left-hand panel) and from
negative to positive (right-hand panel).
As already indicated in case of ∆β(α), the ability of the 5hmC measure to change its sign
can have unwanted results in the context of the screening step, where this measure is the
criterion for selecting CpGs with a substantial amount of 5hmC. In particular, in certain
cases the condition ∆m(α) > 0 is just a matter of an appropriate choice of the correction
term α.
To summarize the results of this section, we state that, on the one hand, the measure
∆m(α) inherits most properties of the measure ∆β(α) which are relevant for the selection
procedure and thus both measures can be used interchangeably while detecting the CpGs
with a substantial level of 5hmC; however, ∆m(α) still lacks an appropriate interpretation
for its values and is dependent on the choice of α in the same way the measure ∆β(α)
is. On the other hand, a wider range of statistical methods may be used for analysis of
∆m(α) what facilitates the calculations, increases the number of research issues that can
be addressed so far and thus increases the applicability of ∆m(α). Here we may also
expect ∆m(α) to outperform ∆β(α) when quantifying low or high levels of 5hmC, just
like m-value outperforms β in such situations [10].
The most crucial characteristic of the hydroxymethylation measures ∆β(α) and ∆m(α)
introduced above is their dependence on the choice of the correction term α which also
impacts the set of CpGs being selected as those with a substantial level of 5hmC. To
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address this issue, and eventually to introduce an alternative 5hmC measure without
such α dependence, we first analyze the behavior of ∆β(α) and ∆m(α) as α varies.
Figure 7: Convergence of ∆β(α) for increasing α: a real data example for a given sample,
tissue and CpG.
As follows from (5), ∆β(α) converges to zero as α increases; see the Appendix 6.1.1
for a discussion and Figure 7 for a graphical presentation of this convergence result. In
practice, this result will imply that, for increasing α, the range of possible ∆β(α) values
will narrow; e.g., the tissue effect as observed in terms of the corresponding ∆β(α) values
may become less observable.
With the convergence result for the measure ∆β(α) obtained above, the crucial question
concerning an impact of increasing values of α on the percentage of CpGs satisfying the
condition ∆β(α) > 0 for a given sample arises. As already demonstrated by Figure 5 and
now by Figure 8, this percentage converges to a positive constant value as α increases;
standard computations verify this limit value to be just the percentage of CpGs satisfying
MBS > MoxBS for a given sample.
5 The same convergence result holds while considering
the percentage of CpGs which satisfy the condition ∆β(α) > 0 over all four given samples:
for an illustration see Figure 9.
5The considered limit value will actually be given by the union of the following two sets
{MBS > MoxBS} ∪ {MBS = MoxBS , UBS < UoxBS},
but for simplicity we ignore the latter set due to its evident irrelevance for the quantification of 5hmC
level and the fact that the percentage of all CpG sites in our real data sets simultaneously satisfying the
conditions
MBS = MoxBS , UBS < UoxBS
for any given sample ranges between 0.0002% and 0.1%.
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Figure 8: Percentage of CpGs satisfying ∆β(α) > 0: a real data example for a given
sample (sample 1) and both tissues. The blue line corresponds to brain tissue, the red
line corresponds to blood tissue; here we consider α = 0, 10, . . . , 8000.
Figure 9: Percentage of CpGs satisfying ∆β(α) > 0 over all given samples: a real data
example for both tissues and α = 0, 10, . . . , 10000. The blue curve corresponds to brain
tissue, the red curve corresponds to blood tissue. The dark blue straight line corresponds
to the percentage of CpG sites satisfying MBS > MoxBS over all given samples for brain
tissue; the dark red straight line corresponds to the analogous percentage for blood tissue.
13
Figure 10: Convergence of ∆m(α) for increasing α: a real data example, for a given
sample, CpG and blood tissue.
Also the convergence result obtained for the measure ∆β(α) is transferable to ∆m(α).
In particular, Figure 10 shows that ∆m(α) converges to some constant value as α goes
to infinity. This result is in accordance with the corresponding convergence result as
obtained for ∆β(α). The only difference is that in case of ∆β(α) this limit will always be
zero, independently of the CpGs, sample, and tissue chosen, whereas in case of ∆m(α)
this limit depends on the CpG, sample, and tissue under consideration.
Inspired by the convergence results obtained for the measures ∆β(α) and ∆m(α) and
trying to overcome the dependence of these measures on the choice of the correction term
α, we propose
∆m∞ = log2
MBS
MoxBS
(= lim
α↑∞
∆m(α)) (9)
as alternative hydroxymethylation measure. Note that this measure is well-defined for all
CpGs satisfying MBS > 0 and MoxBS > 0 simultaneously.
The main advantage of the measure ∆m∞ in comparison with the measure ∆m(α) is
its complete independence of the correction term α; this fact makes the performance of
∆m∞ more robust. Furthermore, the outcomes of this measure have a very intuitive
interpretation. Indeed, we get ∆m∞ > 0 if MBS > MoxBS, i.e., if the global methylated
intensity MBS exceeds the ”adjusted” methylated intensity MoxBS. In all other cases,
we will have ∆m∞ ≤ 0; for instance, ∆m∞ = 0 implies MBS = MoxBS, which can be
interpreted as ‘no 5hmC observed’.
Next, let us address the possible relation between the measures ∆m∞ and ∆m(α). In the
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context of a single CpG, simple computations, which are based on the convergence result
for ∆m(α) obtained above, show that for all CpGs with
UoxBS ≥ UBS
the value of ∆m(α) will be at least as large as the value of ∆m∞, for any α > 0; in all
other case we will get ∆m(α) < ∆m∞; for an illustration see Figure 11.
Figure 11: Measures ∆m(α) (the blue line) versus ∆m∞ (the red line) in case when
UoxBS > UBS (left-hand panel) and in case when UoxBS < UBS (right-hand panel).
The final question that is most crucial in the context of the selection procedure concerns
a relation between the subsets of CpGs satisfying ∆m(α) > 0 and ∆m∞ > 0 respectively.
To address this question, we first recall that, for a given sample, our previous discussion
(see Figure 8) has shown that the subset of CpGs detected by the measure ∆m∞ as those
with a substantial level of 5hmC represents the ”limiting” subset for a sequence of subsets
of CpGs selected by the measure ∆m(α) for increasing α. To formalize this result, for a
given sample we divided the set of all CpGs in several disjoint subsets, and showed that,
for increasing α, the union of these subsets converges to the subset of CpGs satisfying
MBS > MoxBS; see the Appendix 6.2.5.
To summarize the discussion of the present section, we state that, compared to the mea-
sures ∆β(α) and ∆m(α), the measure ∆m∞ can have an advantage for quantifying 5hmC
levels, in particular, due to its intuitive interpretation and independence of the choice of
the correction term α. On the other hand, this measure does not take into account the
unmethylated intensities UBS and UoxBS. This may become an issue even if the role of
these intensities in detection/quantification of the 5hmC levels has not been clarified yet.
Finally, the measure ∆m∞ will detect a greater number of CpGs as exhibiting a positive
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level of 5hmC and thus being relevant for the further analysis than both other 5hmC
measures will. In this sense, the measure ∆m∞ is probably more conservative compared
to the measures ∆m(α) and ∆β(α).
As already mentioned above, the measure ∆m∞ does not take into account unmethylated
intensities UBS and UoxBS. Even if the potential consequences of such modeling are unclear
yet, we are going to address this issue by proposing another measure for the quantification
of the 5hmC level which takes also the unmethylated intensities in account. It is defined
as
∆h = 1− MoxBS + UoxBS
MBS + UBS
, (10)
where MBS + UBS is the global methylation level obtained from the BS-seq method and
MoxBS +UoxBS is the global methylation level derived by means of the oxBS-seq method.
Here we have to assume that MBS + UBS > 0; all CpGs with MBS + UBS = 0 have to be
exclude from the analysis as exhibiting a measurement error. Note that the measure ∆h
can be obtained directly from the measured data, since both quantities MBS + UBS and
MoxBS + UoxBS are immediately observed. Thus, no further data transformations will be
necessary, which reduces the possibility of computational errors.
As follows from its definition, for CpGs with a positive level of 5hmC the measure ∆h
must range between 0 and 1. The CpGs with ∆h < 0 are to be considered as containing
only a unsubstantial level of 5hmC; the CpGs with ∆h > 1 are to be seen as a result of
measurement noise.
When interpreting the values of ∆h in the context of the observed 5hmC level, we can
state the following: Intuitively, for a given sample and CpG, the condition ∆h ≈ 0 implies
MBS+UBS ≈MoxBS+UoxBS and thus the global 5hmC level is negligible in such situations.
In cases, where ∆h ≈ 1 we get MoxBS + UoxBS MBS + UBS and thus the global 5hmC
level has to be high. In particular, larger values of ∆h correspond to larger percentages
of the global 5hmC levels. Altogether, we can interpret ∆h as the proportion/percentage
of 5hmC in the global methylation.
Next, let us analyze whether positive values of the measure ∆h lead to positivity of other
5hmC measures introduced above, and vice versa; this relation is particularly important
in the selection procedure. As (10) implies, the inequality ∆h > 0 holds if
MBS + UBS > MoxBS + UoxBS.
However, the latter inequality is not sufficient to make a statement about the sign of the
measures ∆β(α), ∆m(α), and ∆m∞, and additional assumptions are needed. For more
details see Appendix 6.3.1.
Finally, let us impose a lower threshold for the measure ∆h and consider possible con-
sequences. For instance, we can assume that a given CpG exhibits a substantial level of
5hmC only if the corresponding value of ∆h satisfies the inequality ∆h > c for some con-
stant c > 0. Then a simple calculation shows that the global 5hmC level M5hmC +U5hmC
will be bounded from below by the quantity c(˙MBS + UBS). In other words, by imposing
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a threshold on the measure ∆h we also set a lower bound for the global 5hmC level.
Altogether, in this section we show that the application of the measure ∆h for the quan-
tification of 5hmC levels can be of advantage, since this measure overcomes the limitation
of the 5hmC measures proposed before, and, in particular, does not depend on the choice
of a correction term α. It has an intuitive interpretation of the outcomes in terms of the
observed 5hmC level, and can be easily computed from the measured data.
4 Similarity analyses
In order to compare the outputs of the proposed 5hmC measures without making any
statement about their optimality/performance similarity analyses can be used; the main
tool of such similarity analyses is a similarity measure. The aim of the present section
is to introduce a similarity measure which can be used for pairwise comparison of the
considered 5hmC measures, then apply this similarity measure to our real data sets and
discuss the observed results.
As a reminder: we have two real data sets which correspond to brain and whole blood
tissue respectively; such a tissues’ choice seems to be particularly interesting, since the
brain is known to have the highest level of 5hmC, while blood is known to have the lowest,
see, e.g., [15]. Each data set consists of four independent samples; there are four intensity
vectors,
MBS,MoxBS, UBS, UoxBS,
available for each sample. The data used for analysis was not normalized.
In order to quantify the similarity of two given 5hmC measures in the context of the
screening step, we introduce the similarity measure S that quantifies the pairwise agree-
ment or pairwise similarity of the proposed 5hmC measures ∆β(α), ∆m∞ and ∆h. In
particular, for a given CpG6 we define
S(x1, x2) =
1
n
( n∑
i=1
I{xi1>0}I{xi2>0} +
n∑
i=1
I{xi1≤0}I{xi2≤0}
)
. (11)
Here x1, x2 denote any two considered 5hmC measures, n is the number of samples under
consideration7 and I{x} is the indicator function, defined as
I{x>0} =
{
1 x > 0
0 otherwise.
(12)
Clearly, the similarity measure S in (11) ranges between 0 and 1, where 1 denotes complete
similarity and 0 denotes complete dissimilarity.
At the beginning of real data analysis, we first applied all three 5hmC measures, ∆β(100),
∆m∞ and ∆h, on both real data sets and computed the percentage of CpG sites being
6or for a given sample, if we perform our analysis sample-wise.
7or the number of CpGs for a given sample, if we perform our analysis sample-wise.
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detected as hydroxymethylated by each of these measures; the results of these computa-
tions are presented in Figure 12. This figure depicts the measure ∆h as being the most
conservative while detecting the hydroxymethylated CpGs, since the percentage of CpGs
marked by this measure as being hydroxymethylated and thus relevant for the further
analysis is the largest one.
s1 s2 s3 s4 s1 s2 s3 s4
brain tissue blood tissue
samples samples
Figure 12: Sample-wise application of the 5hmC measures ∆β(100),∆m∞ and ∆h. Both
panels present the percentage of CpGs being detected by each of the considered 5hmC
measures as exhibiting a positive 5hmC level. The left-hand panel describes the results
for brain tissue. On this panel, the light blue bars correspond to the ∆β(100) measure,
the blue bars to the ∆m∞ measure and the dark blue bars to the ∆h measure. The right-
hand panel describes the results for blood tissue. On this panel, the grey bars correspond
to the ∆β(100) measure, the red bars to the ∆m∞ measure and the dark red bars to the
∆h measure.
Next, we applied the measure S in order to address the pairwise similarity of the 5hmC
measures ∆β(100),∆m∞,∆h for each given sample. The obtained results are presented
in Figure 13. In that figure, the highest similarity can be observed between the 5hmC
measures ∆m∞ and ∆h; the measures ∆β(100) and ∆h demonstrate the weakest simi-
larity in terms of the similarity measure S.
In order to discuss the 5hmC measures with respect to their pairwise complete similarity
as well as complete dissimilarity, we performed a pairwise comparison of these measures
for each given CpG. The results of such a comparison are presented in Figures 14 and 15.
In particular, Figure 14 demonstrates the highest level of complete similarity to be ob-
served between the 5hmC measures ∆m∞ and ∆h, independent of the considered tissue.
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Figure 13: Application of the similarity measure S for the pairwise comparison of the
5hmC measures ∆β(100),∆m∞ and ∆h. The similarity was analyzed sample-wise, for
each of four given samples. Both panels present the percentage of CpGs detected by a
pair of the considered 5hmC measures as exhibiting a positive 5hmC level. The left-hand
panel describes the results for brain tissue. On this panel, the light blue bars correspond
to the values of S(∆m∞,∆h), the blue bars to the values of S(∆m∞,∆β(100)) and the
dark blue bars to the values of S(∆β(100),∆h). The right-hand panel describes the results
for blood tissue. On this panel, the grey bars correspond to the values of S(∆m∞,∆h),
the red bars to the values of S(∆m∞,∆β(100)) and the dark red bars to the values of
S(∆β(100),∆h).
On the other hand, Figure 15 shows the highest level of complete dissimilarity between
the 5hmC measures ∆β(100) and ∆h, independent of the considered tissue; the 5hmC
measures ∆m∞ and ∆h demonstrate the lowest level of complete dissimilarity in that
figure. In total, ∆m∞ and ∆h seem to be the two most similar 5hmC measures in the
context of the similarity measure S.
As discussed in the previous section, one of the main limitations of the measure ∆β(α)
is its dependence on the correction term α. Thus we address this dependence in the con-
text of the similarity measure S. As already mentioned earlier, the number of CpG sites
satisfying ∆β(α) > 0 grows with increasing α; see Figure 16 for an illustration.
Changes in the pairwise similarity between two given 5hmC measures, as computed for
all CpGs of a given sample, are described in Figure 17. As observed on that picture, pair-
wise similarity between the 5hmC measure ∆β(α) and the remaining two 5hmC measures
∆m∞ and ∆h increases with increasing α.
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Figure 14: Pairwise complete similarity performed for each given CpG site. The light
blue bar corresponds to the percentage of CpGs with S(∆m∞,∆h) = 1 over all given
samples, in brain tissue. The blue bar corresponds to the percentage of CpGs with
S(∆m∞,∆β(100)) = 1 over all given samples, in brain tissue. The dark blue bar corre-
sponds to the percentage of CpGs with S(∆β(100),∆h) = 1 over all given samples, in
brain tissue. The grey bar corresponds to the percentage of CpGs with S(∆m∞,∆h) = 1
over all given samples, in blood tissue. The red bar corresponds to the percentage of CpGs
with S(∆m∞,∆β(100)) = 1 over all given samples, in blood tissue. The dark red bar cor-
responds to the percentage of CpGs with S(∆β(100),∆h) = 1 over all given samples, in
blood tissue.
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Figure 15: Pairwise complete dissimilarity performed for each given CpG site. The light
blue bar corresponds to the percentage of CpGs with S(∆m∞,∆h) = 0 over all given
samples, in brain tissue. The blue bar corresponds to the percentage of CpGs with
S(∆m∞,∆β(100)) = 0 over all given samples, in brain tissue. The dark blue bar corre-
sponds to the percentage of CpGs with S(∆β(100),∆h) = 0 over all given samples, in
brain tissue. The grey bar corresponds to the percentage of CpGs with S(∆m∞,∆h) = 0
over all given samples, in blood tissue. The red bar corresponds to the percentage of CpGs
with S(∆m∞,∆β(100)) = 0 over all given samples, in blood tissue. The dark red bar cor-
responds to the percentage of CpGs with S(∆β(100),∆h) = 0 over all given samples, in
blood tissue.
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Figure 16: Percentage of CpG sites satisfying ∆β(α) > 0 for increasing α and a given
sample (sample 2). The blue bars correspond to brain tissue, the red bars to blood tissue.
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Figure 17: Application of the similarity measure S for the pairwise comparison of the
5hmC measures ∆β(α),∆m∞ and ∆h; the computation were performed for increasing
values of α. The similarity was analyzed over all given CpGs of a given sample (sample
2). Single bars present the percentage of CpGs being detected by a pair of the considered
5hmC measures as exhibiting a positive 5hmC level. The grey bars correspond to the
comparison of the 5hmC measures ∆β(α) and ∆m∞ on brain tissue; the red bars describe
the results of the analogous comparison on blood tissue. The dark blue bars correspond
to the comparison of the 5hmC measures ∆β(α) and ∆h on brain tissue; the dark red
bars describe the results of the analogous comparison on blood tissue.
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Possible impact of the increasing values of α on the pairwise complete similarity as well as
complete dissimilarity between the considered 5hmC measures is illustrated in Figures 18
and 19. In particular, Figure 18 suggests that the pairwise complete similarity increases
with increasing α; Figure 19 demonstrates decreasing pairwise dissimilarity as α grows.
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Figure 18: Pairwise complete similarity computed for each given CpG site, both given
tissues and increasing values of α. The blue bars correspond to the percentage of CpGs
with S(∆m∞,∆β(α)) = 1 over all given samples, in brain tissue. The red bars correspond
to the percentage of CpGs with S(∆m∞,∆β(α)) = 1 over all given samples, in blood
tissue. Note that complete similarity increases with increasing α.
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Figure 19: Pairwise complete dissimilarity computed for each given CpG site, both given
tissues and increasing values of α. The blue bars correspond to the percentage of CpGs
with S(∆m∞,∆β(α)) = 0 over all given samples, in brain tissue. The red bars correspond
to the percentage of CpGs with S(∆m∞,∆β(α)) = 0 over all given samples, in blood
tissue. Note that complete dissimilarity decreases with increasing α.
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5 Conclusion
Presently, the most applied measure for quantifying a level of 5hmC is the measure ∆β
introduced in [3, 4]. In particular, this measure is applied for detection of the CpG sites
with a positive level of 5hmC; those CpG sites are then considered to be relevant for the
further (also statistical) analysis.
In this paper we first perform a detailed analysis of ∆β, both analytically and data-
based, and discuss a number of limitations which make the application of this measure
while selecting hydroxymethylated CpG sites debatable. To overcome these limitations,
we then propose two alternative 5hmC measures which can be used instead of ∆β. The
properties for these 5hmC measures as well as their relation to the initial measure ∆β are
also discussed, both analytically and on real data. We also propose similarity analyses
which can be used in order to compare the considered 5hmC measures in a certain sense.
Note that our real data analyses are based on the raw data, i.e. the data without any
normalization or pre-processing procedures before the down-stream statistical analysis.
This differs from the common procedures proposed in [3, 4] where only normalized data
was applied. To justify our method, we first recall that the most of our results were
initially obtained analytically and only then confirmed by means of the data analysis.
Thus, similar results can be expected to hold in case of the normalized data. On the
other hand, the normalization of the data may give raise to a number of questions such
as a possible impact of normalization while quantifying the 5hmC level. This impact has
not been investigated so far, and it is not clear whether certain results derived on the
normalized data will be just due to the normalization itself. The choice of an appropriate
normalization method remains an open issue as well.
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6 APPENDIX
6.1 On the 5hmC measure ∆β(α)
6.1.1 Basic properties of ∆β(α)
In this section we summarize basic properties of the measure ∆β(α) defined as
∆β(α) = βBS − βoxBS = MBS
MBS + UBS + α
− MoxBS
MoxBS + UoxBS + α
, (13)
with a correction term α > 0.
First, ∆β(α) in (13) is well-defined for any Mi, Ui ≥ 0, i ∈ {BS, oxBS} and α > 0 and
ranges between -1 and 1.
Since the condition {∆β(α) > 0} plays a key role in the screening step, we need to
determine when this condition will hold. Standard calculations show that {∆β(α) > 0}
is equivalent to the condition
MBS
MoxBS
>
UBS + α
UoxBS + α
. (14)
Thus all CpGs satisfying (14) will also satisfy {∆β(α) > 0}. Further, to capture the
behaviour of ∆β(α) for increasing values of α, we take the limit in (13) and obtain
lim
α↑∞
∆β(α) = 0, (15)
for a given sample and CpG.
6.1.2 ∆β(α) as a function of α
Maxima / minima of the function ∆β(α)
To address possible impact of α on the values of ∆β(α) analytically, we regard ∆β as a
function of α and compute the corresponding derivative
d∆β(α)
dα
=
MoxBS
(MoxBS + UoxBS + α)2
− MBS
(MBS + UBS + α)2
. (16)
This derivative becomes zero in
α0 =
MoxBS
√
MBS + UoxBS
√
MBS −MBS
√
MoxBS − UBS
√
MoxBS√
MoxBS −
√
MBS
. (17)
The quantity in (17) is well-defined for all CpGs with MBS 6= MoxBS and satisfies α0 > 0
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either if8
MBS > MoxBS and
MBS + UBS
MoxBS + UoxBS
>
√
MBS
MoxBS
(18)
or if
MBS < MoxBS and
MBS + UBS
MoxBS + UoxBS
<
√
MBS
MoxBS
. (19)
Further, α0 will be a minimum of ∆β(α) if MoxBS + UoxBS > MBS + UBS, and its maxi-
mum if MoxBS + UoxBS < MBS + UBS.
The function value ∆β(α0) for α0 as in (17) is given by
∆β(α0) =
(
√
MBS −
√
MoxBS)
2
MBS + UBS −MoxBS − UoxBS (20)
and will be positive for all CpGs with MBS + UBS > MoxBS + UoxBS and negative for all
CpGs with MBS + UBS < MoxBS + UoxBS.
Given that the conditions (18) imply MBS + UBS > MoxBS + UoxBS and the conditions
(19) imply MBS +UBS < MoxBS +UoxBS, we summarize that α0 satisfying (18) represents
the maximum of the function ∆β(α), with ∆β(α0) > 0; on the other hand, α0 satisfying
(19) is the minimum of the function ∆β(α), with ∆β(α0) < 0.
Monotonicity of ∆β(α)
One can easily verify that for MoxBS > MBS the function ∆β(α) will be increasing for all
α in the interval (α0,∞); for MoxBS < MBS this function will be increasing for all α in
the interval (−∞, α0).
6.1.3 Sign change of ∆β(α)
Standard calculations show that ∆β(α) may change its sign either for the CpGs with
MBS
MoxBS
>
MBS + UBS
MoxBS + UoxBS
and MoxBS > MBS (21)
or those with
MBS
MoxBS
<
MBS + UBS
MoxBS + UoxBS
and MoxBS < MBS. (22)
8For α0 < 0 we just consider αˆ0 = 0 and compute
∆β(0) =
MBSUoxBS −MoxBSUBS
(MBS + UBS)(MoxBS + UoxBS)
.
This quantity is positive for all CpGs satisfying
MBS
MoxBS
>
UBS
UoxBS
or, equivalently,
MBS
MoxBS
>
MBS + UBS
MoxBS + UoxBS
.
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We can also compute the actual value α∗ > 0, with ∆β(α∗) = 0 and ∆β(α) changing its
sign in α∗9. Indeed, from (13) it follows that ∆β(α∗) = 0 for
α∗ =
MoxBSUBS −MBSUoxBS
MBS −MoxBS . (23)
Note that both (21) and (22) guarantee that α∗ > 0.
Further, the condition (19) leads to the condition (21) and thus for all CpGs satisfying
(19) the measure ∆β(α) will indeed change its sign in α∗; the same result holds for the
conditions (18) and (22).
6.2 On the 5hmC measures ∆m(α) and ∆m∞
6.2.1 Basic properties
When defined by
∆m = mBS −moxBS = log2
βBS
1− βBS − log2
βoxBS
1− βoxBS , (24)
the measure ∆m is well-defined for any Mi, Ui ≥ 0, i ∈ {BS, oxBS}, if α > 0. For α = 0
∆m is also well-defined, but only if Mi and Ui do not vanish simultaneously. This result
conforms to the fact that the measure ∆β(α) is well-defined for any Mi, Ui ≥ 0, i ∈
{BS, oxBS} as α > 0; for α = 0, MBS,MoxBS, UBS, UoxBS must not vanish at the same
time for ∆β(α) to be well-defined. Thus the 5hmC measures ∆β(α) and ∆m are well-
defined on the same sets of CpGs.
For the measure ∆m(α) calculated as
∆m(α) = log2
MBS
MoxBS
+ log2
UoxBS + α
UBS + α
. (25)
to be well-defined, we have to differentiate between the following two situations:
(a) α > 0. In these cases the conditions
MBS 6= 0 and MoxBS 6= 0 (26)
must hold simultaneously, since otherwise the term log2
MBS
MoxBS
in (25) will become
infinite.
(b) α = 0. In these cases the conditions
MBS 6= 0,MoxBS 6= 0, UBS 6= 0, UoxBS 6= 0 (27)
must hold simultaneously, since otherwise both terms log2
MBS
MoxBS
and log2
UBS+α
UoxBS+α
in (25) will become infinite.
9Simple calculations show that α0 > α
∗ for all CpGs satisfying both inequalities MoxBS + UoxBS >
MBS + UBS and MoxBS > MBS simultaneously or those with MoxBS + UoxBS < MBS + UBS and
MoxBS < MBS .
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Given that only a few CpGs in our real data sets do not satisfy these conditions, we used
the definition (25) of ∆m in all our discussions.
Further, the condition ∆m(α) > 0 is equivalent to the inequality
MBS
MoxBS
>
UBS + α
UoxBS + α
. (28)
This inequality is exactly the same as the inequality (14) that has been shown to imply
∆β(α) > 0. Thus, for any fixed values of MBS, MoxBS, UBS and UoxBS the measures
∆m(α) and ∆β(α) must have the same sign. Indeed, ∆m > 0 implies
βBS
βoxBS
· 1− βoxBS
1− βBS > 1
which is equivalent to βBS > βoxBS or, alternatively, ∆β > 0; on the other hand, ∆β > 0
leads to the inequality (28) and thus ∆m > 0 follows.
Similarly to the case of ∆β(α), the convergence of ∆m(α) for increasing α can easily be
derived from (25), which gives
lim
α↑∞
∆m(α) = log2
MBS
MoxBS
. (29)
Since ∆m(α) is monotone in α (see below), we can consider log2
MBS
MoxBS
as an upper or
lower bound for ∆m(α), depending on whether UBS > UoxBS or UBS < UoxBS.
6.2.2 ∆m(α) versus ∆β(α): no functional dependence
In this section we show that there is no transformation between the measures ∆m(α) and
∆β(α) that would render ∆m(α) as a function of ∆β(α). To see this, we consider an
example with βoxBS ranging between 0 and 0.85 and βBS = βoxBS + 0.15. In such setting,
∆β(α) will be constant, but ∆m(α) will change its values for changing βoxBS(α); thus
∆m(α) is not a function of ∆β(α). For an illustration of this result see Figure 20.
Figure 20: ∆m(α) as a function of βoxBS. The x-axis corresponds to the βoxBS(α) values
and the y-axis corresponds to the ∆m(α) values. Note that in this example ∆β(α) is
constant for all values of βoxBS(α).
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6.2.3 ∆m(α) as a function of α
We consider ∆m(α) as a function of α and compute the derivative
d∆m(α)
dα
=
UBS − UoxBS
(UBS + α)(UoxBS + α) ln 2
(30)
This derivative is obviously positive for all CpGs with UBS ≥ UoxBS; thus for such CpGs
∆m(α) will increase with increasing α. On the other hand, for all CpGs with UBS < UoxBS
∆m(α) is decreasing in α.
Since on the one hand the derivative (30) does not have zeros and on the other hand
α ≥ 0 must hold, we set the minimum of ∆m(α) to be attained at α = 0 for all CpGs
with UBS ≥ UoxBS ; the increasing values of α in this case will lead to increasing values
of ∆m(α).
For the CpGs with UBS < UoxBS, the maximal value of ∆m(α) will be attained at α = 0;
the increasing values of α in this case will correspond to decreasing values of ∆m(α).
This last fact also implies that all CpGs with UBS < UoxBS and ∆m(0) < 0 should be
excluded from the data set immediately as irrelevant for the further analysis, even before
the screening step is completed.
6.2.4 Sign change of ∆m(α)
Standard calculations show that ∆m(α) changes its sign either for the CpGs with
MBS > MoxBS and
MBS + UBS
MoxBS + UoxBS
>
MBS
MoxBS
(31)
or those with
MBS < MoxBS and
MBS + UBS
MoxBS + UoxBS
<
MBS
MoxBS
. (32)
Note that these are exactly the conditions (21) and (22) that imply the sign changes for
the measure ∆β(α).
Here we also compute the value α∗ > 0 for which ∆m(α∗) = 0 and ∆m(α) changes its
sign at α∗. Indeed, from (25) it follows that ∆m(α∗) = 0 for
α∗ =
MoxBSUBS −MBSUoxBS
MBS −MoxBS , (33)
which is exactly the same α∗ as obtained in (23) for ∆β(α).
6.2.5 On the relation between the subsets {∆m(α) > 0} and {∆m∞ > 0}
The aim of this section is to show analytically that, for a given sample and increasing
α > 0, the subset of CpGs satisfying ∆m∞ > 0 will approximately become a ”limiting”
subset for a sequence of subsets of CpGs satisfying ∆m(α) > 0. The discussion above
should hold for a given sample.
First, let us assume that ∆m∞ > 0 for a given sample and CpG. Then we want to show
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that for α > 0 large enough, it will hold ∆m(α) > 0 for this sample and CpG, too.
The condition ∆m∞ > 0 evidently leads to MBS > MoxBS. On the other hand, while
considering the second term in the expression
∆m(α) = log2
MBS
MoxBS
+ log2
UoxBS + α
UBS + α
,
we state that
∀ > 0 exists a α0 > 0 such that
∣∣∣ log2 UoxBS + αUBS + α
∣∣∣ < . (34)
Thus for all α > α0 we will get ∆m(α) > 0.
Next, let us assume that ∆m(α) > 0 for all α > 0 large enough. Then, with (34), it must
hold
log2
MBS
MoxBS
≥ 0.
This latter expression implies either MBS > MoxBS, and, as a result, ∆m
∞ > 0, or
MBS = MoxBS.
10
Similar considerations show that in cases when α > 0 increases, the subset of CpG sites
satisfying {∆m(α) > 0} over all given samples (approximately) approaches the subset of
CpG sites which satisfy ∆m∞ > 0 over all given samples; for an illustration see Figure 9.
6.3 On the 5hmC measure ∆h
6.3.1 On the relation between the subsets {∆h > 0}, {∆m(α) > 0} and {∆m∞ >
0}
In this section we analyze how the positivity of the 5hmC ∆h implies the positivity of two
other 5hmC measures. First of all, as follows from the definition of ∆h, the inequality
∆h > 0 holds for all CpGs with
MBS + UBS > MoxBS + UoxBS.
Further, if we have the inequalities MBS + UBS > MoxBS + UoxBS and MBS > MoxBS
holding simultaneously, both measures ∆h and ∆m∞ will be positive.
For CpGs satisfying
MBS + UBS > MoxBS + UoxBS, MBS > MoxBS, and UBS < UoxBS
the 5hmC measure ∆m(α) will be positive for any α > 0. If UBS > UoxBS, then the sign
of ∆m(α) will depend on the choice of α. In particular, we will have ∆m(α) > 0 for
α > α∗, with α∗ as in (33); otherwise ∆m(α) will be negative.
For CpGs with
MBS + UBS > MoxBS + UoxBS and MBS < MoxBS and UBS > UoxBS,
we will get ∆h > 0, but the measures ∆m∞ and ∆m(α) will have negative outcomes.
10As a reminder: for MBS = MoxBS the condition ∆m(α) > 0 will hold only if UBS < UoxBS . But,
due to our discussion above, we agreed to ignore the set {MBS = MoxBS , UBS < UoxBS}.
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